STOCK TITAN

Merit Med Sys Inc - MMSI STOCK NEWS

Welcome to our dedicated page for Merit Med Sys news (Ticker: MMSI), a resource for investors and traders seeking the latest updates and insights on Merit Med Sys stock.

Overview

Merit Medical Systems, Inc. (NASDAQ: MMSI) is a globally recognized manufacturer and distributor of advanced medical devices that are instrumental in diagnostic, cardiology, and interventional radiology procedures. With a long-standing history in the development of disposable medical tools, Merit operates from its headquarters in South Jordan, Utah and serves a worldwide customer base through a combination of direct sales and distributor networks. The company is renowned for its commitment to precision, quality, and innovation in the medical device industry, continuously enhancing its product portfolio to meet the evolving demands of minimally invasive procedures.

Products and Services

At its core, Merit Medical Systems develops, manufactures, and markets a diverse range of proprietary disposable medical devices. These devices are vital components in procedures such as angioplasty, stent placement, discography, and embolization therapies. Key product categories include:

  • Inflation and Angioplasty Devices: Engineered for precision in opening narrowed vessels, these devices support interventions such as stent placement and discography.
  • Diagnostic and Therapeutic Catheters: Designed for use in both diagnostic and therapeutic settings in cardiology and radiology, offering versatility and reliability.
  • Guide Wires: Essential for the careful placement of balloon angioplasty catheters, ensuring safe navigation through coronary arteries.
  • Embolic Devices: Including innovative embolic products that enhance the accuracy and efficiency of procedures that occlude blood vessels to manage bleeding or treat abnormal tissue growth.
  • Ancillary Products and Custom Kits: These encompass angiography accessories and specifically tailored angiography kits that support a wide range of clinical applications.

The company’s product development not only addresses the critical needs of diagnostic and interventional procedures but also extends to applications in oncology, critical care, and endoscopy. By integrating state-of-the-art design with robust manufacturing processes, Merit Medical ensures that its products deliver reliable performance and improved patient outcomes in fast-paced clinical environments.

Market Position and Business Model

Merit Medical Systems stands out within the competitive landscape by focusing on innovation, quality, and comprehensive clinical support. The company generates revenue primarily through direct sales channels in the United States and Europe as well as via a global network of distributors. This diversified sales model allows Merit to directly engage with hospitals, clinics, and physicians, ensuring that its advanced medical devices are consistently positioned as trusted solutions in critical care. By maintaining strict quality standards and achieving key regulatory clearances, Merit has built a reputation for excellence and continues to bolster its market position through strategic product portfolio expansions and acquisitions that enhance its capabilities in high-margin segments such as electrophysiology and cardiac rhythm management.

Research, Innovation, and Clinical Support

Innovation is at the forefront of Merit Medical’s strategy. The company invests in research and development to bring new product solutions to market, supported by extensive clinical trials and regulatory reviews. Merit collaborates with medical professionals and thought leaders to design devices that not only meet current clinical needs but also address emerging challenges in patient care. This focus on innovation is complemented by a strong clinical support team that works closely with healthcare practitioners to provide education, training, and technical assistance, ensuring that the advantages of Merit’s devices are fully realized in real-world clinical settings.

Competitive Landscape

Operating in a dynamic and highly competitive medical device market, Merit Medical Systems differentiates itself by combining technical expertise with a deep understanding of clinical practices. While the industry features multiple players offering various medical technologies, Merit’s specialization in interventional and diagnostic procedures, along with its commitment to continuous innovation and quality assurance, establishes it as an authoritative and trusted partner in patient care. The company’s ongoing investments in new technologies and strategic acquisitions further strengthen its competitive position, supporting its role as a key contributor to advancements in minimally invasive treatment.

Regulatory Excellence and Global Reach

Merit Medical’s success is underpinned by its adherence to stringent regulatory standards. With multiple products gaining clearance or approval from major regulatory agencies, the company demonstrates its commitment to safe and effective medical device manufacturing. This regulatory excellence, combined with a robust global distribution network, enables Merit to serve a broad spectrum of healthcare institutions and maintain enduring partnerships with clinicians worldwide.

Conclusion

In summary, Merit Medical Systems, Inc. is a pivotal force in the field of healthcare technology. Through its innovative medical devices, unwavering commitment to quality, and strategic global presence, Merit empowers healthcare professionals to deliver more reliable, precise, and minimally invasive treatments. The company continues to be a cornerstone in advancing interventional, diagnostic, and therapeutic procedures, reinforcing its position as a trusted partner within the medical community.

Rhea-AI Summary
Merit Medical Systems, Inc. introduces Continued Growth Initiatives Program with financial targets for the three-year period ending December 31, 2026. Targets include 5-7% organic revenue growth, 20-22% non-GAAP operating margin, and $400 million cumulative free cash flow generation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
none
-
Rhea-AI Summary
Merit Medical Systems, Inc. (MMSI) receives FDA clearance for SCOUT MD Surgical Guidance System, a breakthrough in breast cancer care. The system targets tumor location in multiple dimensions for precise excision, reducing the need for repeat surgeries and improving patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
-
Rhea-AI Summary
Merit Medical Systems, Inc. announces the enrollment of the first patient in its multicenter clinical trial comparing genicular artery embolization (GAE) to corticosteroid injections for knee osteoarthritis. The MOTION study aims to evaluate the safety and effectiveness of Embosphere Microspheres for pain relief, with the potential to set a new standard in knee-pain management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
none
Rhea-AI Summary
Merit Medical Systems, projected a preliminary unaudited revenue of approximately $1.255 to $1.259 billion for the year ended December 31, 2023, showing a projected increase of approximately 9.0% to 9.4% compared to the previous year. The projected preliminary unaudited constant currency revenue for the same period increased in the range of approximately 9.6% to 9.9%. The company plans to announce its financial results for the fourth quarter and year ended December 31, 2023, and issue fiscal year 2024 guidance after the close of the stock market on Wednesday, February 28, 2024. The company's ticker symbol is MMSI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.34%
Tags
-
Rhea-AI Summary
Merit Medical Systems, Inc. (NASDAQ: MMSI) Chairman and CEO Fred Lampropoulos will present at the J.P. Morgan 42nd Annual Healthcare Conference on January 8, 2024, at 4:30pm PT. The company's live audio webcast will be available on the investor section of the Merit Medical website www.merit.com. Mr. Lampropoulos expressed excitement to share the company's mission of product innovation to improve patients' lives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
conferences
-
Rhea-AI Summary
Merit Medical Systems, Inc. (NASDAQ: MMSI) outlines the CEO succession planning process, with Fred Lampropoulos continuing as CEO and President through December 31, 2025. A special steering committee is developing a succession plan, with Korn Ferry assisting in identifying potential candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
Rhea-AI Summary
Merit Medical Systems, Inc. (MMSI) announced the pricing of $650.0 million aggregate principal amount of 3.00% Convertible Senior Notes due 2029 in a private placement to qualified institutional buyers. The offering was upsized from the previously announced offering of $550 million aggregate principal amount of notes. The notes will bear interest at 3.00% per year, payable semi-annually. The initial conversion rate of the notes will be 11.5171 shares of Merit’s common stock per $1,000 principal amount of notes, representing a premium of approximately 32.5% over the last reported sale price of Merit’s common stock on the Nasdaq Global Select Market on December 5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
-
Rhea-AI Summary
Merit Medical Systems, Inc. (Nasdaq: MMSI) plans to offer $550.0 million aggregate principal amount of Convertible Senior Notes due 2029 in a private placement. The notes will be senior unsecured obligations, with interest payable semiannually in arrears, and will be convertible to cash, shares of Merit's common stock, or a combination of both. The company intends to use the net proceeds for general corporate purposes, including repayment of existing debt, sales and marketing activities, research and development, and potential acquisitions. Merit also plans to enter into capped call transactions to reduce potential dilution to its common stock upon conversion of notes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.37%
Tags
none
-
Rhea-AI Summary
Merit Medical Systems reports Q3 2023 revenue of $315.2 million, up 9.8% YoY. Raises fiscal year 2023 financial guidance. GAAP operating margin increases to 11.1% in Q3 2023. Non-GAAP operating margin increases to 18.3% in Q3 2023. GAAP EPS increases to $0.44 in Q3 2023. Non-GAAP EPS increases to $0.75 in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.68%
Tags
Rhea-AI Summary
Merit Medical Systems expands Maestro Microcatheter product line with new longer length for radial embolization procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none

FAQ

What is the current stock price of Merit Med Sys (MMSI)?

The current stock price of Merit Med Sys (MMSI) is $95.79 as of April 9, 2025.

What is the market cap of Merit Med Sys (MMSI)?

The market cap of Merit Med Sys (MMSI) is approximately 6.0B.

What core products does Merit Medical Systems, Inc. offer?

Merit Medical develops and manufactures a wide range of disposable medical devices including inflation devices, diagnostic and therapeutic catheters, guide wires, embolic devices, and custom angiography kits.

In which clinical areas does Merit specialize?

The company primarily serves the fields of cardiology and radiology by providing devices used in diagnostic and interventional procedures. Additionally, its products support oncology, critical care, and endoscopy applications.

How does Merit Medical generate revenue?

Merit Medical generates revenue through a combination of direct sales in major regions such as the United States and Europe, supported by a global network of distributors and clinical support teams.

What sets Merit Medical apart in the competitive medical device market?

Merit Medical is distinguished by its commitment to innovation, stringent quality standards, regulatory excellence, and a diversified product portfolio that addresses complex clinical needs.

How does the company ensure the quality and safety of its products?

The company adheres to rigorous regulatory standards and employs robust manufacturing processes, ensuring that its devices meet the high demands of minimally invasive procedures and clinical applications.

What role does research and development play at Merit Medical?

Research and development is a cornerstone of Merit Medical’s strategy. The company continuously invests in R&D to innovate new products, enhance existing technologies, and collaborate with clinicians to address emerging healthcare challenges.

How does Merit Medical support healthcare professionals?

Beyond product development, Merit Medical offers extensive clinical support and education, ensuring that healthcare professionals receive the training and technical assistance necessary to effectively integrate its devices into patient care.

What is Merit Medical's global market presence?

Merit Medical operates globally, with direct sales operations in key regions and a vast network of distributors, enabling it to provide advanced medical devices to hospitals, clinics, and healthcare providers around the world.
Merit Med Sys Inc

Nasdaq:MMSI

MMSI Rankings

MMSI Stock Data

5.99B
57.70M
2.57%
106%
5.11%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
SOUTH JORDAN